statement of deviation or variation in utilization of funds, if any
AMANTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Amanta Healthcare has submitted its quarterly utilization report for IPO proceeds raised in September 2025 (₹126 crore). The company confirms there is NO deviation or variation in how the IPO funds have been used. Of the ₹7,000 lakh allocated for the SteriPort manufacturing line, ₹3,080.86 lakh has been utilized so far. The SVP manufacturing line allocation of ₹3,013.11 lakh remains fully unutilized. Issue expenses came in higher than estimated by ₹358.38 lakh (₹2,284.81 lakh actual vs ₹1,926.43 lakh planned), which was adjusted by reducing the General Corporate Purpose allocation from ₹660.46 lakh to ₹302.08 lakh. The Audit Committee and auditors have no comments on the utilization.
This is a routine compliance filing with no negative implications. The company has deployed ₹3,080.86 lakh (~44%) of the SteriPort capital expenditure budget within the first quarter of deployment, indicating the manufacturing expansion is underway. The reallocation between issue expenses and general corporate purposes is a standard accounting adjustment with no impact on core business operations.